Doravirine

Major

Doravirine Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Doravirine Atidarsagene Autotemcel Lenmeldy Interference with the manufacturing of atidarsagene autotemcel Details Doravirine Avacopan Tavneos Increased CYP3A4 substrate exposure Details Doravirine Bosentan Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Cenobamate Xcopri Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Doravirine Conivaptan Vaprisol Increased CYP3A substrate exposure Details Doravirine Dabrafenib Tafinlar Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Dipyrone Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Efavirenz Decreased doravirine plasma concentration and reduced efficacy; increased risk of doravirine resistance Details Doravirine Elagolix Orilissa Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Doravirine Etravirine Intelence Decreased doravirine plasma concentration and reduced efficacy; increased risk of doravirine resistance Details Doravirine Etuvetidigene Autotemcel An increased risk of interference with the manufacturing of etuvetidigene autotemcel Details Doravirine Itraconazole Sporanox Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Doravirine Lesinurad Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Letermovir Prevymis Increased CYP3A substrate exposure Details Doravirine Lopinavir Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Lorlatinib Lorbrena Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Mifepristone Korlym Increased CYP3A4 substrate exposure Details Doravirine Mitapivat Aqvesme Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Modafinil Provigil Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Nafcillin Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Nevirapine Viramune Decreased doravirine plasma concentration and reduced efficacy; increased risk of doravirine resistance Details Doravirine Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Doravirine Pacritinib Vonjo® Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Pexidartinib Turalio Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Doravirine Repotrectinib Augtyro Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Rifabutin Mycobutin Reduced doravirine exposure, reduced efficacy and an increased risk of doravirine resistance Details Doravirine Sotorasib Lumakras Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Doravirine Telotristat Ethyl Xermelo Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Thioridazine Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Voriconazole Vfend Increased CYP3A4 substrates exposure and an increased efficacy of CYP3A4 substrates-related adverse effects Details Doravirine Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Doravirine Nafcillin Injection Unipen® Injection Reduced doravirine exposure and reduced efficacy of doravirine Details